International Society for the Study of Women's Sexual Health

ISSWSH Annual Meeting
February 25-28, 2016


Charleston, SC - USA
Charleston Marriott

ISSWSH is a multidisciplinary, academic, and scientific organization whose purposes are:

To provide

opportunities for communication among scholars, researchers, and practitioners about women's sexual function and sexual experience...

To support

the highest standards of ethics and professionalism in research, education, and clinical practice of women's sexuality, and ...

To provide

the public with accurate information about women's sexuality and sexual health.

UPCOMING MEETING

ISSWSH Annual Meeting 2016

  February 25-28, 2016  17 days left
  Marriott, Charleston, SC - USA
Read more...
Register Now!

ISSWSH Fall Course 2016

  October 21-23, 2016  256 days left
  DoubleTree Hilton Hotel, Scottsdale, AZ - USA
Read more...

LATEST NEWS

Follow up on the exciting news that flibanserin was approved by the FDA on August 18, 2015
  PUBLISHED: TUESDAY, OCTOBER 06, 2015
Dear ISSWSH Member,

We would like to follow up on the exciting news that flibanserin, a drug for acquired, generalized hypoactive sexual desire disorder (HSDD) developed by Sprout Pharmaceuticals, was approved by the FDA on August 18, 2015. As previously informed, flibanserin will be marketed with the trade name Addyi.

As a multidisciplinary, scientific organization dedicated to research, clinical practice, and education, ISSWSH would like to inform you that healthcare prescribers and pharmacies can now complete training to become certified to prescribe or dispense the medication through the Addyi Risk Evaluation and Mitigation Strategy (REMS) Program. Read more ...
2015 Consensus terminology and classification of persistent vulvar pain
  PUBLISHED: WEDNESDAY, SEPTEMBER 09, 2015
Dear ISSWSH Members

Since the previous terminology of vulvodynia was accepted by the International Society for the Study of Vulvovaginal Disorders (ISSVD) in 2003, studies have explored possible causative factors and treatment options. The International Society for the Study of Women's Sexual Health (ISSWSH), The International Society for the Study of Vulvovaginal Disorders (ISSVD) and the International Pelvic Pain Society (IPPS) believed there was an unmet medical need for a comprehensive, evidence-based set of vulvovaginal pain diagnoses that can be easily utilized by both expert and non-expert healthcare providers to establish diagnoses in their patients and to guide treatment. Therefore we discussed the possibility of revision of 2003 terminology and organized an ISSWSH sponsored international meeting in order to reach a consensus on the terminology of vulvar pain, April 8 - 9, 2015 in Annapolis, Maryland. The American College of Obstetricians and Gynecologists (ACOG) and the National Vulvodynia Association (NVA) were also represented.
Read more ...
Flibanserin approved as the FIRST pharmacologic treatment option for women suffering from hypoactive sexual desire disorder
  PUBLISHED: TUESDAY, AUGUST 18, 2015

Dear ISSWSH members,

It is with tremendous excitement that we share the announcement that flibanserin, a drug for acquired, generalized hypoactive sexual desire disorder (HSDD) developed by Sprout Pharmaceuticals, was approved by the FDA on August 18, 2015. This follows the June 4, 2015 meeting of their Advisory Committee whose members voted 18-6 for approval.

Read more ...

Latest Tweets

Bio-Identical Hormones for #menopause: Sorting Myths from Facts https://t.co/pzhR4h3eMw ISSWSH
Feb 24 Community Program SEX IN OUR CITY an intimate afternoon of conversation about sexual health issues and answer https://t.co/Wi6kgVDRo5 ISSWSH
Attractive men had more short-term #sex #partners while attractive women had more long-term partners in this study https://t.co/CLb9Y3ESPG ISSWSH

Contact Details

ISSWSH Executive Office - Status Plus LLC
PO Box 1233
Lakeville, MN 55044
USA

Phone: +1 (218) 461 5115
Fax: +1 (612) 808 0491
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.